PIM2 Promotes the Development of Ovarian Endometriosis by Enhancing Glycolysis and Fibrosis

Endometriosis is a common gynecological disorder characterized by the presence of the endometrial glands and the stroma outside the uterine cavity. The disease affects reproductive function and quality of life in women of reproductive age. Endometriosis is similar to tumors in some characteristics, such as glycolysis. PIM2 can promote the development of tumors, but the mechanism of PIM2 in endometriosis is still unclear. Therefore, our goal is to study the mechanism of PIM2 in endometriosis. Through immunohistochemistry, we found PIM2, HK2, PKM2, SMH (smooth muscle myosin heavy chain), Desmin, and α-SMA (α-smooth muscle actin) were strongly expressed in the ovarian endometriosis. In endometriotic cells, PIM2 enhanced glycolysis and fibrosis via upregulating the expression of PKM2. Moreover, the PIM2 inhibitor SMI-4a inhibited the development of endometriosis. And we established a PIM2 knockout mouse model of endometriosis to demonstrate the role of PIM2 in vivo. In summary, our study indicates that PIM2 promotes the development of endometriosis. PIM2 may serve as a promising therapeutic target for endometriosis.

 

Comments:

Your study suggests that PIM2, a protein involved in promoting the development of tumors, plays a role in endometriosis. You conducted immunohistochemistry and found that PIM2, along with other markers such as HK2, PKM2, SMH, Desmin, and α-SMA, was strongly expressed in ovarian endometriosis. In endometriotic cells, PIM2 was found to enhance glycolysis (a metabolic process) and fibrosis by upregulating the expression of PKM2. Furthermore, when you used the PIM2 inhibitor SMI-4a, you observed inhibition of endometriosis development. Additionally, you created a PIM2 knockout mouse model of endometriosis to provide evidence of the role of PIM2 in vivo.

Based on your findings, you propose that PIM2 could be a potential therapeutic target for endometriosis. Further research and exploration of PIM2 inhibitors or other interventions targeting PIM2 may hold promise for the treatment of endometriosis.

Related Products

Cat.No.	Product Name	Information
S8005	SMI-4a	SMI-4a (TCS PIM-1 4a) is a potent inhibitor of Pim1 with IC50 of 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.

Related Targets

Pim